Ligand Pharma to buy Vernalis for just under £33m in cash
9th Aug 2018 15:12
(Sharecast News) - AIM-listed Vernalis has agreed to be bought by Ligand UK, a subsidiary of California-based Ligand Pharmaceuticals, for 6.2p per share in cash, valuing the company at around £32.67m.
Read moreVernalis says US FDA accepts CCP-08 for full review
21st Dec 2016 13:03
(ShareCast News) - Vernalis and Tris Pharma said the US Food and Drug Administration (FDA) has accepted the CCP-08 New Drug Application (NDA) for full review. This triggered a milestone payment from AIM-quoted Vernalis to Tris. The FDA had set a Prescription Drug User Fee Act (PDUFA) target date
Read moreVernalis shares down on disappointing full year
29th Sep 2016 11:09
(ShareCast News) - Vernalis posted its audited results for the year to 30 June on Thursday, with revenue dropping to £12.03m from £13.71m in the year to 30 June 2015. The AIM-traded firm reported an operating loss before exceptional items of £26.22m, widening significantly from £8.22m in the prior y
Read moreMoxatag supply issues looming for Vernalis
19th May 2016 16:40
(ShareCast News) - Vernalis warned investors on Thursday of looming supply issues with an upcoming drug it will distribute - Moxatag - as its Ireland-based supplier Suir Pharma was placed into provisional liquidation. The AIM-traded company said information was limited at this time, but it had been
Read moreVernalis raises £40m in placing
26th Apr 2016 11:41
(ShareCast News) - Specialty pharmaceutical company Vernalis announced a £40m placing on Tuesday, through the issue of 80 million new ordinary shares at a price of 50p apiece. The AIM-traded firm said the placing shares have been conditionally placed by the joint bookrunners with institutional inves
Read moreVernalis hires AstraZeneca marketeer to lead Tuzistra operation in US
21st Apr 2016 14:44
(ShareCast News) - Vernalis has appointed 24-year AstraZeneca veteran Sandford 'Sandy' Sommer as president and chief operating officer of its US operation, Vernalis Therapeutics. Sommer most recent role was as president of AstraZeneca's Colombia operations, following a variety of leadership roles, i
Read moreVernalis drops into red after investment in cough treatment
17th Mar 2016 12:12
(ShareCast News) - Shares in Vernalis sank to an 11-month low after the biotech company posted a half-year loss as its first prescription cough cold product, Tuzistra XR, launched during what has proved a very mild flu season in the USA. Revenue was up 7% to £6.1m in the six months to 31 December, b
Read moreVernalis acquires rights to Pragma's MOXATAG treatment
2nd Oct 2015 16:31
(ShareCast News) - Pharmaceutical group Vernalis has completed the acquisition of the US rights to the amoxicillin extended-release tablet brand MOXATAG from Pragma Pharmaceuticals. The London-listed company said it has made an undisclosed up-front payment in cash for the rights, with a further paym
Read moreVernalis slumps after disappointing Phase II results
20th Aug 2015 10:10
(ShareCast News) - Vernalis said results of the phase II proof-of-concept study of its fatty acid amide hydrolase inhibitor, which is being investigated as a treatment for neuropathic pain, failed to meet its pain-reduction primary endpoint. The biopharmaceutical research and development company sai
Read moreFTSE 250 movers: Miners drag index down, Synthomer spikes higher
11th Aug 2015 14:15
(ShareCast News) - The FTSE 250 index was by late on Tuesday afternoon giving up some of the gains made late the day before, as commodities-focused stocks were hit by China's devaluation and corporate news received mixed reviews. By 1540 BST the index was down 0.47% at 17,677.29 points, with Vedanta
Read moreFriday broker round-up:
14th Nov 2014 19:34
TSB Banking: Shore Capital reiterates buy with a target price for 325p. Vernalis: Canaccord Genuity ups target to 66p from 56p and reiterates buy. Aggreko: Panmure Gordon and Investec reiterate hold. Gemfields: Numis initiates coverage with a buy recommendation and 70p target price. Ithaca Energy
Read moreThursday broker round-up UPDATE
14th Aug 2014 09:39
Admiral Group: Deutsche Bank reduces target price from 1330p to 1260p and maintains a hold recommendation. Balfour Beatty: Deutsche Bank lowers target price from 250p to 245p keeping its hold recommendation. Betfair: Jefferies raises target price from 1175p to 1230p maintaining a buy recommendatio
Read moreSector movers: Weak results, outlook from Glaxo sink pharma stocks
23rd Jul 2014 14:17
A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a
Read moreTuesday broker round-up UPDATE
22nd Jul 2014 09:37
Abcam: N+1 Singer places both its target price (prev.: 346p) and its sell recommendation under review. Amiad Water Systems: Oriel lowers target price from 350p to 340p and retains a buy recommendation. Ashmore Group: Espirito Santo ups target price from 371p to 404p, while downgrading to neutral.
Read moreMonday broker round-up UPDATE
7th Jul 2014 09:26
Balfour Beatty: Berenberg lowers target price from 290p to 280p and retains a buy recommendation. UBS lowers target price from 230p to 225p and keeps a neutral rating. Barclays: Citi lowers target price from 305p to 300p and keeps its sell recommendation. Clinigen: Investec cuts target price from
Read more